Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6

被引：2
|
作者：
Patel, M. R. [1 ,2 ]
Hamilton, E. P. [2 ]
Piha-Paul, S. A. [3 ]
Henry, J. [4 ]
Banerji, U. [6 ]
Al Hallak, M. N. [5 ,7 ]
Okada, H. [8 ]
Qian, M. [9 ]
Zhang, X. [10 ]
Said, N. [11 ]
Chatikhine, V. [12 ]
Fontana, E. [13 ]
机构：
[1] Florida Canc Specialists, Drug Dev Unit, Sarasota, FL USA
[2] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[4] HealthOne, Sarah Cannon Res Inst, Drug Dev Unit, Denver, CO USA
[5] Inst Canc Res, Drug Dev Unit, London, England
[6] Royal Marsden Hosp, London, England
[7] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA
[8] Daiichi Sankyo Inc, Clin Sci, Basking Ridge, NJ USA
[9] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA
[10] Daiichi Sankyo Inc, Quantitat Clin Pharmacol, Basking Ridge, NJ USA
[11] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA
[12] Daiichi Sankyo Inc, Early Clin Dev, Basking Ridge, NJ USA
[13] Sarah Cannon Res Inst SCRI UK, Drug Dev, London, England
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.677
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
610O
引用
收藏
页码：S488 / S489
页数：2
相关论文
共 50 条
  • [41] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
    Zhang, L.
    Ma, Y.
    Zhao, Y.
    Fang, W. F.
    Zhao, H.
    Huang, Y.
    Yang, Y.
    Hou, X.
    Wen, Z.
    Zhang, S.
    Wang, J.
    Xiao, S.
    Wang, H.
    Zhu, H.
    Olivo, M. S.
    Zhu, Y.
    ANNALS OF ONCOLOGY, 2023, 34
  • [42] Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
    Jhaveri, K.
    Han, H.
    Dotan, E.
    Oh, D-Y.
    Ferrario, C.
    Tolcher, A.
    Lee, K-W.
    Liao, C-Y.
    Kang, Y-K.
    Kim, Y. H.
    Hamilton, E.
    Spira, A.
    Patel, N.
    Karapetis, C.
    Rha, S. Y.
    Boyken, L.
    Woolery, J.
    Bedard, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S749 - S750
  • [43] First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC).
    Gazzah, Anas
    Cousin, Sophie
    Boni, Valentina
    Ricordel, Charles
    Kim, Tae Min
    Kim, Jin-Soo
    Helissey, Carole
    Gardeazabal, Itziar
    Chadjaa, Mustapha
    Allard, Aurore
    Yoruk, Semra
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors
    Subbiah, V.
    Falchook, G.
    Davis, A. A.
    Wang, J. S.
    de Miguel, M.
    Santoro, A.
    Maur, M.
    Aljumaily, R.
    Boni, V.
    de Speville, B. Doger
    Sun, Y.
    Du, Y.
    Lakshmikanthan, S.
    Bedse, G.
    Ward, A.
    Zweidler-McKay, P.
    Gandhi, L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S72 - S73
  • [45] Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/ metastatic solid tumors
    Ma, Fei
    Qiu, Fuming
    Tong, Zhongsheng
    Wang, Jiani
    Tan, Yinuo
    Bai, Rui
    Zhou, Qing
    Xing, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Dose escalation and expansion results from the phase I study of F0024, a trophoblast cell-surface antigen 2 (TROP2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
    Du, Yiqun
    Meng, Yanchun
    Wang, Jingfen
    Wang, Ying
    Wu, Fan
    Chen, Yu
    Chen, Lilin
    Qing, Lihua
    Qiao, Yaya
    Liu, Kezhen
    Sun, Wenyi
    Li, Xiaowen
    Zhang, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] A phase lb, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.
    Burris, Howard A.
    Barve, Minal A.
    Hamilton, Erika Paige
    Bardia, Aditya
    Soliman, Hatem Hussein
    Jarlenski, Donna
    Mosher, Rebecca
    Bergstrom, Donald Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Zolbetuximab+mFOLFOX6 as First-Line (1L) treatment for patients (Pts) with Claudin-18.2+(CLDN18.2+) / HER2-Locally Advanced (LA) unresectable or metastatic Gastric or Gastroesophageal Junction (mG/GEJ) adenocarcinoma: primary results from Phase 3 SPOTLIGHT Study
    Lordick, F.
    Shitara, K.
    Bang, Y. -J
    Enzinger, P.
    Ilson, D.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R. -H
    Aprile, G.
    Xu, J.
    Chao, J.
    Pazo-Cid, R.
    Kang, Y. K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Arozullah, A.
    Park, J. W.
    Ajani, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 115 - 116
  • [49] A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
    Daver, Naval G.
    Erba, Harry P.
    Papadantonakis, Nikolaos
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Konopleva, Marina Y.
    Sloss, Callum M.
    Culm-Merdek, Kerry
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [50] ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
    De Miguel, M.
    Yamamoto, N.
    Raimbourg, J.
    Cho, B. C.
    Gottfried, M.
    Stemmer, S. M.
    Goldman, J. W.
    Blaney, M. E.
    Jennaro, T.
    Vasilopoulos, A.
    Li, R. R.
    Freise, K. J.
    Aristide, M. R. Neagu
    Morrison-Thiele, G.
    Hunter, Z. N.
    Burns, M.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2024, 35 : S805 - S806
12345